↓ Skip to main content

Dove Medical Press

Article Metrics

Clinical applications of somatostatin analogs for growth hormone-secreting pituitary adenomas

Overview of attention for article published in Patient preference and adherence, January 2014
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
18 Mendeley
Title
Clinical applications of somatostatin analogs for growth hormone-secreting pituitary adenomas
Published in
Patient preference and adherence, January 2014
DOI 10.2147/ppa.s53930
Pubmed ID
Authors

Yong-Hong Zhu, Ji-wen Wang, Ying Li, Zhi-gang Mao, Xiao-bing Jiang, Bing-bing Song, Xin Wang, Hai-jun Wang, Bin Hu

Abstract

Excessive growth hormone (GH) is usually secreted by GH-secreting pituitary adenomas and causes gigantism in juveniles or acromegaly in adults. The clinical complications involving cardiovascular, respiratory, and metabolic systems lead to elevated morbidity in acromegaly. Control of serum GH and insulin-like growth factor (IGF) 1 hypersecretion by surgery or pharmacotherapy can decrease morbidity. Current pharmacotherapy includes somatostatin analogs (SAs) and GH receptor antagonist; the former consists of lanreotide Autogel (ATG) and octreotide long-acting release (LAR), and the latter refers to pegvisomant. As primary medical therapy, lanreotide ATG and octreotide LAR can be supplied in a long-lasting formulation to achieve biochemical control of GH and IGF-1 by subcutaneous injection every 4-6 weeks. Lanreotide ATG and octreotide LAR provide an effective medical treatment, whether as a primary or secondary therapy, for the treatment of GH-secreting pituitary adenoma; however, to maximize benefits with the least cost, several points should be emphasized before the application of SAs. A comprehensive assessment, especially of the observation of clinical predictors and preselection of SA treatment, should be completed in advance. A treatment process lasting at least 3 months should be implemented to achieve a long-term stable blood concentration. More satisfactory surgical outcomes for noninvasive macroadenomas treated with presurgical SA may be achieved, although controversy of such adjuvant therapy exists. Combination of SA and pegvisomant or cabergoline shows advantages in some specific cases. Thus, an individual treatment program should be established for each patient under a full evaluation of the risks and benefits.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 6%
Unknown 17 94%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 28%
Researcher 4 22%
Professor > Associate Professor 2 11%
Student > Bachelor 2 11%
Unspecified 1 6%
Other 4 22%
Readers by discipline Count As %
Medicine and Dentistry 8 44%
Agricultural and Biological Sciences 5 28%
Linguistics 1 6%
Biochemistry, Genetics and Molecular Biology 1 6%
Computer Science 1 6%
Other 2 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 January 2014.
All research outputs
#2,909,330
of 4,507,509 outputs
Outputs from Patient preference and adherence
#267
of 422 outputs
Outputs of similar age
#75,942
of 122,658 outputs
Outputs of similar age from Patient preference and adherence
#28
of 42 outputs
Altmetric has tracked 4,507,509 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 422 research outputs from this source. They receive a mean Attention Score of 2.3. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 122,658 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.